arrow
A

Antonio D'Alessio

humanitas clinical and research center-irccs
H指数:36
被引数:5,095

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.

髓系免疫抑制表型定义了肝细胞癌对阿替利珠单抗联合贝伐珠单抗的原发耐药性。

2026-06-150
OAAI
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study

使用高级机器学习方法预测阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌的结局:一项回顾性队列研究

2026-02-120
OAAI
The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver Cancer

2024年国际肝脏移植学会和国际肝脏肿瘤协会关于肝脏移植治疗肝癌的共识建议

2026-01-010
OA
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study

伦伐替尼对比索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌的二线治疗:LEVIATHAN 研究

2025-09-230
OAAI
Hepatocellular carcinoma in people living with HIV

人类免疫缺陷病毒感染者中的肝细胞癌

2025-04-300
OAAI
Outcomes of durvalumab with or without tremelimumab in routine clinical practice according to HIMALAYA Trial Eligibility: preliminary results of the international DT-real study
2025-02-010
PRE
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
2024-11-211
PRE
Electric quadrupole excitation strengths of 112,116,120Sn from nuclear resonance fluorescence
2024-11-060
PRE
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma

在肝细胞癌的早期阶段提供辅助和新辅助治疗

2024-10-223
OAAI
Comprehensive cancer genome profiling as supportive tool for treatment decision-making in patients with metastatic solid tumors: Real-world evidence-based meta-analysis and nationwide cancer registry data implementation

全面癌症基因组分析作为转移性实体瘤患者治疗决策的支持工具:基于真实世界证据的荟萃分析和全国癌症登记数据实施

2024-09-010
PRE
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

肝功能失代偿是使用阿特珠单抗联合贝伐单抗治疗的肝细胞癌患者死亡率的主要驱动因素: 成功抗病毒治疗的影响

2024-07-195
PRE
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

经动脉化疗栓塞治疗肝细胞癌后派姆单抗的安全性和初步疗效: PETAL Ib期研究

2024-04-053
OAAI
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

肝细胞癌患者与其他晚期实体瘤患者免疫治疗相关肝损伤的特征和结局

2024-03-0111
OA
Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma
2024-02-010
PRE
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

肝细胞癌免疫治疗疗效和安全性性别差异的meta分析和真实世界队列研究

2024-02-016
OAAI